Role of nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic vascular dysfunction

Current Vascular Pharmacology

Volumn 3, Issue 3, 2005, Pages 247-252

  Mabley, Jon G ^a   Garcia Soriano, Francisco ^b  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Diabetes; Endothelial; Nitric oxide; Peroxynitrite; Poly (ADP ribose) polymerase; Superoxide; Vascular

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; FP 15; GLICLAZIDE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRIC OXIDE; NOX 101; PEROXYNITRITE; POLYOL; PROTEIN KINASE C; REACTIVE NITROGEN SPECIES; SCAVENGER; SINGLE STRANDED DNA; SUPEROXIDE; TEMPOL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; BLOOD VESSEL TONE; CELL DAMAGE; CELL RESPIRATION; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DNA STRAND BREAKAGE; ENDOTHELIUM CELL; ENZYME ACTIVATION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REGULATORY MECHANISM; REVIEW; STROKE;

ANIMALS; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; HYPERGLYCEMIA; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 21644484482     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161054368571     Document Type: Review

References (97)

1. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67(1):3-21.
2. Schellhase KG, Koepsell TD, Weiss NS, Wagner EH, Reiber GE. Glucose screening and the risk of complications in Type 2 diabetes mellitus. J Clin Epidemiol 2003; 56(1):75-80.
3. Schellhase KG, Koepsell TD, Weiss NS. Glycemic control and the risk of multiple microvascular diabetic complications. Fam Med 2005; 37(2):125-30.
4. Ruderman NB, Williamson JR, Brownlee M. Glucose and diabetic vascular disease. Faseb J 1992; 6(11):2905-14.
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414(6865):813-20.
6. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003; 26(5):1589-96.
7. Szabo E, Virag L, Bakondi E, Gyure L, Hasko G, Bai P, et al. Peroxynitrite production, DNA breakage, and poly(ADP-ribose) polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity. J Invest Dermatol 2001; 117(1):74-80.
8. Furchgott RF. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep 1999; 19(4):235-51.
9. Ignarro LJ. Nitric oxide: a unique endogenous signaling molecule in vascular biology. Biosci Rep 1999; 19(2):51-71.
10. De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Clin Nutr Metab Care 2000; 3(6):453-67.
11. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87(10):840-4.
12. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22(1):36-52.
13. Szabo C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, et al. Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 2002; 106(21):2680-6.
14. Cosentino F, Eto M, De Paolis P, van der Loo B, Bachschmid M, Ullrich V, et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 2003; 107(7):1017-23.
15. Ungvari Z, Pacher P, Kecskemeti V, Papp G, Szollar L, Koller A. Increased myogenic tone in skeletal muscle arterioles of diabetic rats. Possible role of increased activity of smooth muscle Ca2+ channels and protein kinase C. Cardiovasc Res 1999; 43(4):1018-28.
16. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130(5):963-74.
17. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86(9):E85-90.
18. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287(19):2570-81.
19. King GL. The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in diabetes. Ann Med 1996; 28(5):427-32.
20. Carter AM, Grant PJ. Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus. Diabet Med 1997; 14(6):423-32.
21. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404(6779):787-90.
22. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C - dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49(11):1939-45.
23. Da Ros R, Assaloni R, Ceriello A. Antioxidant therapy in diabetic complications: what is new? Curr Vasc Pharmacol 2004; 2(4):335-41.
24. Tesfamariam B, Palacino JJ, Weisbrod RM, Cohen RA. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol 1993; 21(2):205-11.
25. Diederich D, Skopec J, Diederich A, Dai FX. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol 1994; 266(3 Pt 2):H1153-61.
26. Angulo J, Rodriguez-Manas L, Peiro C, Neira M, Marin J, Sanchez-Ferrer CF. Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 1998; 358(5):529-37.
27. Rodriguez-Manas L, Angulo J, Peiro C, Llergo JL, Sanchez-Ferrer A, Lopez-Doriga P, et al. Endothelial dysfunction and metabolic control in streptozotocin-induced diabetic rats. Br J Pharmacol 1998; 123(8):1495-502.
28. Sakamoto S, Minami K, Niwa Y, Ohnaka M, Nakaya Y, Mizuno A, et al. Effect of exercise training and food restriction on endothelium-dependent relaxation in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous NIDDM. Diabetes 1998; 47(1):82-6.
29. Giugliano D, Marfella R, Acampora R, Giunta R, Coppola L, D'Onofrio F. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 1998; 21(4):631-6.
30. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96(1):25-8.
31. Spitaler MM, Graier WF. Vascular targets of redox signalling in diabetes mellitus. Diabetologia 2002; 45(4):476-94.
32. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19(3):257-67.
33. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 2003; 140-141:105-12.
34. Virag L, Szabo E, Gergely P, Szabo C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett 2003; 140-141:113-24.
35. Greenacre SA, Ischiropoulos H. Tyrosine nitration: localisation, quantification, consequences for protein function and signal transduction. Free Radic Res 2001; 34(6):541-81.
36. Halliwell B. What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett 1997; 411(2-3):157-60.
37. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998; 391(6665):393-7.
38. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, et al. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem 1994; 269(42):26066-75.
39. Rubbo H. Nitric oxide and peroxynitrite in lipid peroxidation. Medicina (B Aires) 1998; 58(4):361-6.
40. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 1999; 263(3):681-4.
41. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem, Biophys 1992; 298(2):431-7.
42. Yamakura F, Taka H, Fujimura T, Murayama K. Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J Biol Chem 1998; 273(23):14085-9.
43. Szabo C, Ohshima H. DNA damage induced by peroxynitrite: subsequent biological effects. Nitric Oxide 1997; 1(5):373-85.
44. Zingarelli B, Salzman AL, Szabo C. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 1998; 83(1):85-94.
45. Matata BM, Galinanes M. Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA binding activity. J Biol Chem 2002; 277(3):2330-5.
46. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001; 44(7):834-8.
47. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, Heinecke JW. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 2001; 107(7):853-60.
48. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002; 25(8):1439-43.
49. Ceriello A. Nitrotyrosine: new findings as a marker of postprandial oxidative stress. Int J Clin Pract Suppl 2002(129):51-8.
50. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87(12):1123-32.
51. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 2001; 50(6):1414-24.
52. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 2003; 162(6):1995-2004.
53. Lorenzi M, Montisano DF, Toledo S, Barrieux A. High glucose induces DNA damage in cultured human endothelial cells. J Clin Invest 1986; 77(1):322-5.
54. Shimoi K, Okitsu A, Green MH, Lowe JE, Ohta T, Kaji K, et al. Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells. Mutat Res 2001; 480-481:371-8.
55. Sheu ML, Ho FM, Yang RS, Chao KF, Lin WW, Lin-Shiau SY, et al. High Glucose Induces Human Endothelial Cell Apoptosis Through a Phosphoinositide 3-Kinase-Regulated Cyclooxygenase-2 Pathway. Arterioscler Thromb Vasc Biol 2005.
56. Srinivasan S, Hatley ME, Bolick DT, Palmer LA, Edelstein D, Brownlee M, et al. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia 2004; 47(10):1727-34.
57. Srinivasan S, Yeh M, Danziger EC, Hatley ME, Riggan AE, Leitinger N, et al. Glucose regulates monocyte adhesion through endothelial production of interleukin-8. Circ Res 2003; 92(4):371-7.
58. Srinivasan S, Bolick DT, Hatley ME, Natarajan R, Reilly KB, Yeh M, et al. Glucose regulates interleukin-8 production in aortic endothelial cells through activation of the p38 mitogen-activated protein kinase pathway in diabetes. J Biol Chem 2004; 279(30):31930-6.
59. Manduteanu I, Voinea M, Serban G, Simionescu M. High glucose induces enhanced monocyte adhesion to valvular endothelial cells via a mechanism involving ICAM-1, VCAM-1 and CD18. Endothelium 1999; 6(4):315-24.
60. Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001; 281(5):E924-30.
61. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003; 52(11):2795-804.
62. Piconi L, Quagliaro L, Da Ros R, Assaloni R, Giugliano D, Esposito K, et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost 2004; 2(8):1453-9.
63. Ulker S, McMaster D, McKeown PP, Bayraktutan U. Antioxidant vitamins C and E ameliorate hyperglycaemia-induced oxidative stress in coronary endothelial cells. Diabetes Obes Metab 2004; 6(6):442-51.
64. Cinar MG, Ulker S, Alper G, Evinc A. Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats. Pharmacology 2001; 62(1):56-64.
65. Vallejo S, Angulo J, Peiro C, Sanchez-Ferrer A, Cercas E, Llergo JL, et al. Prevention of endothelial dysfunction in streptozotocin-induced diabetic rats by gliclazide treatment. J Diabetes Complications 2000; 14(4):224-33.
66. Fava D, Cassone-Faldetta M, Laurenti O, De Luca O, Ghiselli A, De Mattia G. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes. Diabet Med 2002; 19(9):752-7.
67. De Mattia G, Laurenti O, Fava D. Diabetic endothelial dysfunction: effect of free radical scavenging in Type 2 diabetic patients. J Diabetes Complications 2003; 17(2 Suppl):30-5.
68. Nassar T, Kadery B, Lotan C, Da'as N, Kleinman Y, Haj-Yehia A. Effects of the superoxide dismutase-mimetic compound tempol on endothelial dysfunction in streptozotocin-induced diabetic rats. Eur J Pharmacol 2002; 436(1-2):111-8.
69. Pieper GM, Dembny K, Siebeneich W. Long-term treatment in vivo with NOX-101, a scavenger of nitric oxide, prevents diabetes-induced endothelial dysfunction. Diabetologia 1998; 41(10):1220-6.
70. Szabó C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, et al. Part I: Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: Studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 2002; 8(10):571-580.
71. Ueda K, Hayaishi O. ADP-ribosylation. Annu Rev Biochem 1985; 54:73-100.
72. Lautier D, Lagueux J, Thibodeau J, Menard L, Poirier GG. Molecular and biochemical features of poly (ADP-ribose) metabolism. Mol Cell Biochem 1993; 122(2):171-93.
73. Szabo C, Dawson VL. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia- reperfusion. Trends Pharmacol Sci 1998; 19(7):287-98.
74. Berger NA. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res 1985; 101(1):4-15.
75. Virag L, Szabo C. The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors. Pharmacol Rev 2002; 54(3):375-429.
76. Abdelkarim GE, Gertz K, Harms C, Katchanov J, Dirnagl U, Szabo C, et al. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med 2001; 7(3):255-60.
77. Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G, et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 2002; 300(3):862-7.
78. Pacher P, Cziraki A, Mabley JG, Liaudet L, Papp L, Szabo C. Role of poly(ADP-ribose) polymerase activation in endotoxin-induced cardiac collapse in rodents. Biochem Pharmacol 2002; 64(12):1785-91.
79. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C. The Role of Poly(ADP-Ribose) Polymerase Activation in the Development of Myocardial and Endothelial Dysfunction in Diabetes. Diabetes 2002; 51(2):514-21.
80. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001; 7(1):108-113.
81. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 2001; 89(8):684-91.
82. Brownlee M. A radical explanation for glucose-induced beta cell dysfunction. J Clin Invest 2003; 112(12):1788-90.
83. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003; 112(7):1049-57.
84. Sirover MA. Minireview. Emerging new functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. Life Sci 1996; 58(25):2271-7.
85. Sirover MA. Role of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in normal cell function and in cell pathology. J Cell Biochem 1997; 66(2):133-40.
86. Sirover MA. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta 1999; 1432(2):159-84.
87. Berry MD, Boulton AA. Glyceraldehyde-3-phosphate dehydrogenase and apoptosis. J Neurosci Res 2000; 60(2):150-4.
88. Brune B, Mohr S. Protein thiol modification of glyceraldehyde-3-phosphate dehydrogenase and caspase-3 by nitric oxide. Curr Protein Pept Sci 2001; 2(1):61-72.
89. Ishitani R, Tajima H, Takata H, Tsuchiya K, Kuwae T, Yamada M, et al. Proapoptotic protein glyceraldehyde-3-phosphate dehydrogenase: a possible site of action of antiapoptotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(2):291-301.
90. Chuang DM, Hough C, Senatorov VV. Glyceraldehyde-3-Phosphate Dehydrogenase, Apoptosis, and Neurodegenerative Diseases. Annu Rev Pharmacol Toxicol 2004.
91. Li F, Szabo C, Pacher P, Southan GJ, Abatan OI, Charniauskaya T, et al. Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia. 2004.
92. Obrosova IG, Pacher P, Szabo C, Zsengeller Z, Hirooka H, Stevens MJ, et al. Aldose Reductase Inhibition Counteracts Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase Activation in Tissue Sites for Diabetes Complications. Diabetes 2005; 54(1):234-42.
93. Obrosova IG, Mabley JG, Zsengeller Z, Charniauskaya T, Abatan OI, Groves JT, et al. Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. Faseb J 2004.
94. Obrosova IG, Li F, Abatan OI, Forsell MA, Komjati K, Pacher P, et al. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 2004; 53(3):711-20.
95. Obrosova IG, Minchenko AG, Frank RN, Seigel GM, Zsengeller Z, Pacher P, et al. Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int J Mol Med 2004; 14(1):55-64.
96. Sugawara R, Hikichi T, Kitaya N, Mori F, Nagaoka T, Yoshida A, et al. Peroxynitrite decomposition catalyst, FP15, and poly(ADP-ribose) polymerase inhibitor, PJ34, inhibit leukocyte entrapment in the retinal microcirculation of diabetic rats. Curr Eye Res 2004; 29(1):11-6.
97. Xiao CY, Chen M, Zsengeller Z, Szabo C. Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor. J Pharmacol Exp Ther 2004; 310(2):498-504.